A Congressional Budget Office estimate of the cost of the Trump administration’s plans to scrap rebates to PBMs and drug plans in Medicare Part D will bolster arguments of opponents but isn’t likely to deter HHS.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,